List of Excipients in Branded Drug NITAZOXANIDE

Generic Drugs Containing NITAZOXANIDE

Company	Ingredient	NDC	Excipient
e5 Pharma LLC	nitazoxanide	13517-135	D&C YELLOW NO. 10 ALUMINUM LAKE
e5 Pharma LLC	nitazoxanide	13517-135	FD&C BLUE NO. 2 ALUMINUM LAKE
e5 Pharma LLC	nitazoxanide	13517-135	FD&C YELLOW NO. 6 ALUMINUM LAKE
e5 Pharma LLC	nitazoxanide	13517-135	HYPROMELLOSE 2910
e5 Pharma LLC	nitazoxanide	13517-135	LECITHIN, SOYBEAN
e5 Pharma LLC	nitazoxanide	13517-135	MAGNESIUM STEARATE
e5 Pharma LLC	nitazoxanide	13517-135	POLYVINYL ALCOHOL

What are the Most Frequently-Used Excipients in NITAZOXANIDE?

# Of NDCs	Excipient
3	D&C YELLOW NO. 10 ALUMINUM LAKE
1	FD&C BLUE NO. 2
2	FD&C BLUE NO. 2 ALUMINUM LAKE
1	FD&C YELLOW NO. 6
2	FD&C YELLOW NO. 6 ALUMINUM LAKE
4	HYPROMELLOSE 2910
2	LECITHIN, SOYBEAN

Nitazoxanide Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Nitazoxanide is a short-course antiparasitic drug with an established safety profile, generic competition, and limited remaining product exclusivity in the United States. The strongest commercial opportunities are formulation-led: pediatric taste masking, reconstitutable suspension stability, improved dissolution, food-independent exposure, and differentiated presentations such as dispersible tablets or unit-dose sachets. Nitazoxanide is not a biologic, so biosimilar risk does not apply. The main regulatory pathway for improved products is an ANDA where pharmaceutical equivalence and bioequivalence can be demonstrated, or a 505(b)(2) application where the formulation introduces clinically meaningful differences.

What is nitazoxanide and how does its formulation affect commercial value?

Nitazoxanide is a synthetic nitrothiazolyl-salicylamide antiparasitic. After oral administration, it is rapidly hydrolyzed to tizoxanide, the principal active metabolite. The U.S. product Alinia is approved for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in adults and children at least one year old.[1]

The marketed U.S. dosage forms are:

Product	Strength	Dosage form	Primary population
Alinia	500 mg	Film-coated tablet	Adults and children 12 years and older
Alinia	100 mg/5 mL	Oral suspension	Children 1 to 11 years and patients unable to swallow tablets

The standard treatment duration is three days. The short regimen limits the value of extended-release technology but increases the importance of immediate usability, dosing accuracy, tolerability, and complete course adherence.

Nitazoxanide has low aqueous solubility. Its absorption improves when administered with food, according to the U.S. prescribing information.[1] This creates a formulation opportunity because a product with less dependence on meal timing could improve convenience and reduce variability in exposure.

The commercial formulation problem is therefore defined by four characteristics:

1. Low aqueous solubility and dissolution sensitivity.
2. Rapid conversion to tizoxanide.
3. Pediatric use beginning at one year of age.
4. Short treatment courses where taste, dosing accuracy, and administration convenience affect completion.

What excipients are used in marketed nitazoxanide products?

The marketed formulations use conventional oral excipients rather than high-complexity drug-delivery systems.

Nitazoxanide tablets

The tablet platform generally uses a combination of:

• Diluent and filler excipients.
• Starch-based disintegrants.
• Microcrystalline cellulose or related compression aids.
• Lubricants.
• Film-coating materials.
• Opacifiers and colorants where applicable.

This platform is inexpensive, scalable, and suitable for generic development. Its limitation is that conventional tablets do not directly solve the active ingredient’s dissolution characteristics or food effect.

Nitazoxanide oral suspension

The suspension platform relies on:

• Aqueous vehicle.
• Suspending agents, such as xanthan gum or a comparable polymer.
• Sweeteners.
• Preservatives.
• Buffering agents.
• Flavoring systems.
• Wetting agents where needed.

The suspension is supplied as a powder for reconstitution. This design reduces the stability burden associated with storing nitazoxanide in water but shifts risk to reconstitution accuracy, sedimentation, redispersibility, microbial control, and in-use stability.[1]

The product’s sucrose content is commercially relevant. A sugar-free formulation could target children with diabetes, dental-risk concerns, institutional formularies, and markets that favor lower-sugar pediatric medicines.

What excipient strategies can improve nitazoxanide performance?

The most commercially credible strategies are those that solve a defined product problem without creating a disproportionate regulatory burden.

1. Particle-size reduction and wetting systems

Micronization or nanocrystal technology can increase surface area and improve dissolution. Suitable excipient systems may include:

• Poloxamers.
• Sodium lauryl sulfate at controlled levels.
• Polysorbates.
• Lecithin or phospholipid wetting systems.
• Polyvinylpyrrolidone-based stabilizers.
• Hydroxypropyl cellulose or hydroxypropyl methylcellulose.

The primary development risks are aggregation, polymorphic conversion, excess surfactant exposure, and poor powder flow. For a three-day product, a modest dissolution improvement may be commercially valuable if it supports bioequivalence under fed and fasted conditions or reduces exposure variability.

2. Amorphous solid dispersions

An amorphous solid dispersion can improve apparent solubility by dispersing nitazoxanide in a polymer matrix. Candidate polymers include:

• Hypromellose acetate succinate.
• Hydroxypropyl methylcellulose.
• Polyvinylpyrrolidone-vinyl acetate copolymer.
• Soluplus-type graft copolymers.
• Polyethylene glycol in selected systems.

This approach has greater formulation complexity than micronization. The critical quality attributes are amorphous content, recrystallization resistance, dissolution maintenance during storage, residual solvent, and powder processability.

An amorphous dispersion is more defensible as an intellectual-property platform than a routine tablet excipient change. A product sponsor could seek protection for the solid dispersion, polymer ratio, manufacturing process, dissolution profile, or stability range.

3. Lipid-based delivery

Self-emulsifying or self-microemulsifying systems can address poor aqueous solubility. Potential excipients include medium-chain triglycerides, mono- and diglycerides, nonionic surfactants, and cosolvents.

The commercial fit is less direct for conventional pediatric therapy. Liquid lipid systems can create taste, oxidative-stability, capsule-fill, and dose-volume problems. They may be more appropriate for a higher-strength adult capsule, a differentiated oral liquid, or a 505(b)(2) product targeting food-independent absorption.

4. Cyclodextrin complexation

Cyclodextrins can improve apparent solubility and may support a clear or low-volume liquid dosage form. The main commercial constraints are excipient cost, dose loading, renal safety considerations for certain cyclodextrins, and the need to demonstrate that complexation improves product performance rather than only laboratory solubility.

A cyclodextrin-based pediatric formulation could have value if it provides:

• Reduced dose volume.
• Better taste masking.
• Improved reconstitution.
• Lower sedimentation.
• More consistent dosing.

5. Taste masking and pediatric acceptability

Taste masking is likely the highest-value excipient opportunity because nitazoxanide is administered to young children and the treatment course is short. Potential systems include:

• Ion-exchange resin complexes.
• Polymer coatings.
• Lipid barriers.
• Cyclodextrin inclusion complexes.
• Multiparticulates in sachets or sprinkle capsules.
• High-intensity sweetener and flavor combinations.

A successful pediatric product must balance taste, dose uniformity, dissolution, and swallowability. Excessive coating can delay release or reduce bioavailability. Sweetener systems also need evaluation for osmolality, dental exposure, gastrointestinal tolerance, and compatibility with preservatives.

6. Sugar-free and preservative-optimized suspensions

A sugar-free suspension can use sorbitol, glycerol, maltitol, or a combination of bulking agents and high-intensity sweeteners. This strategy can improve formulary access but may increase osmolality and gastrointestinal effects.

Preservative selection must account for pH, container compatibility, microbial challenge results, and preservative efficacy over the full in-use period. Sodium benzoate is common in oral liquids, but its concentration and labeling implications require control, particularly in pediatric products.

What formulations are protected by nitazoxanide patents?

The original nitazoxanide compound and early pharmaceutical products were developed before the current generic market. The commercially important U.S. exclusivity period has expired, and the drug is now exposed to generic competition. Formulation patents, if active in a particular jurisdiction, must be evaluated separately from the original compound protection.

Potentially protectable subject matter includes:

Formulation area	Possible claim scope	Commercial value
Nanocrystals	Particle-size distribution, stabilizer ratio, dissolution profile	Medium to high
Solid dispersion	Polymer identity, drug loading, amorphous stability	High if clinically differentiated
Pediatric suspension	Preservative, buffer, viscosity, redispersibility	Medium
Taste masking	Coating composition, resin complex, multiparticulate design	High in pediatric markets
Sugar-free liquid	Sweetener system, osmolality, stability	Medium
Dispersible tablet	Disintegration, wetting, flavor, dose uniformity	Medium to high
Unit-dose sachet	Powder flow, reconstitution, moisture protection	Medium
Combination product	Nitazoxanide with another active ingredient	Potentially high, but requires new clinical and regulatory support

Routine use of known excipients is usually weak patent subject matter unless the formulation produces an unexpected technical result. The stronger strategy is to connect the excipient composition to a measurable performance claim, such as improved dissolution, reduced food effect, enhanced stability, or superior taste scores.

When does nitazoxanide lose exclusivity and what is the Orange Book status?

Nitazoxanide’s U.S. new-chemical-entity exclusivity and the original Alinia product protection are no longer the primary commercial barriers. FDA-approved generic competition exists for nitazoxanide dosage forms, subject to the product-specific reference listed drug and current FDA approval records.[2]

The commercial status can be summarized as follows:

Issue	U.S. position
Regulatory category	Prescription drug
Reference product	Alinia
Active ingredient	Nitazoxanide
Main dosage forms	500 mg tablets and 100 mg/5 mL suspension
Original FDA approval	2002
NCE exclusivity	Expired
Generic pathway	ANDA for equivalent products
Biosimilar pathway	Not applicable
Orange Book relevance	Listed patents and exclusivity must be checked by product and edition
Main remaining barriers	Formulation know-how, manufacturing scale, pediatric acceptability, market access

Because Orange Book listings can change by edition and application, any launch analysis must distinguish expired patents from currently listed patents and regulatory exclusivity. A generic applicant may use Paragraph IV certification where a listed patent remains relevant, but the commercial significance depends on the patent’s expiration date, statutory stay, litigation outcome, and settlement terms.[2,3]

Which companies are challenging nitazoxanide exclusivity?

Nitazoxanide is a genericized small molecule rather than a current high-value biologic or specialty product. Generic competition is therefore more likely to arise through ANDA filings than through biosimilar development or major Paragraph IV litigation.

The relevant competitive groups include:

• Established generic manufacturers with oral-solid-dose capacity.
• Pediatric liquid specialists.
• Contract development and manufacturing organizations.
• Regional manufacturers in Latin America, Asia, Africa, and the Middle East.
• Companies developing repurposed nitazoxanide products for viral or inflammatory indications.

A Paragraph IV challenge can be commercially relevant if it targets a surviving formulation patent rather than the expired original compound rights. For a basic tablet or conventional suspension, the litigation barrier is generally lower than for a proprietary nanocrystal, taste-masked multiparticulate, or clinically differentiated formulation.

No biosimilar risk exists because nitazoxanide is a chemically synthesized small molecule. The relevant competitors are generic tablets, oral suspensions, and potential reformulated products.

What patent litigation and settlement risks affect nitazoxanide?

The principal litigation risks are formulation-specific.

Paragraph IV litigation

A Paragraph IV filing may challenge:

• Listed formulation patents.
• Method-of-use patents.
• Polymorph or solid-state claims.
• Drug-release or dissolution claims.
• Pediatric dosage-form claims.

The risk is highest when a branded product has an active Orange Book-listed patent with a plausible infringement theory. It is lower when the branded product is protected only by expired compound patents or routine formulation features.

Method-of-use patents

Nitazoxanide has been investigated for indications beyond its original antiparasitic approvals. A method-of-use patent may protect treatment of a specific viral infection, inflammatory disease, or patient subgroup. Such patents do not necessarily block an ANDA for the approved antiparasitic indication if the applicant uses a proper section viii statement and omits the protected indication from labeling.

Settlement agreements

A settlement could include an authorized generic, delayed generic entry, licensing rights, supply arrangements, or restrictions on a particular indication. Any settlement involving a listed patent should be reviewed against FTC and FDA disclosure requirements and the specific terms of the agreement.[3]

What is the FDA regulatory pathway for a new nitazoxanide excipient product?

The pathway depends on whether the new product remains pharmaceutically equivalent to the reference drug.

ANDA pathway

An ANDA is the most efficient route for a product that matches the reference product in active ingredient, dosage form, strength, route, and therapeutic equivalence requirements. Excipients can differ, but the applicant must show that the differences do not affect safety, efficacy, bioequivalence, or performance.

This pathway is best suited to:

• A lower-cost tablet.
• A conventional generic suspension.
• A sugar-free suspension with demonstrated bioequivalence.
• A dispersible tablet that meets applicable equivalence requirements.

505(b)(2) pathway

A 505(b)(2) application may be appropriate where the formulation changes the product’s clinical use or requires reliance on existing findings combined with new data. Examples include:

• Food-independent absorption.
• A novel pediatric delivery system.
• A substantially lower-volume oral liquid.
• A new route or dosage form.
• A clinically meaningful modified-release product.

The 505(b)(2) route may provide a period of regulatory exclusivity for qualifying new clinical investigations, but it does not recreate broad compound exclusivity.

How strong is the patent estate for nitazoxanide formulation products?

The base nitazoxanide patent estate is commercially weak after generic entry. The opportunity lies in new formulation claims rather than the original active ingredient.

Asset type	Patent strength	Development burden	Likely commercial use
Conventional tablet excipient substitution	Low	Low	Price competition
Sugar-free suspension	Low to medium	Moderate	Pediatric and institutional niches
Taste-masked multiparticulate	Medium to high	Moderate to high	Pediatric differentiation
Nanocrystal formulation	Medium to high	High	Bioavailability and dissolution claims
Amorphous solid dispersion	High if stable and differentiated	High	Premium reformulation
Food-independent formulation	High if clinically demonstrated	High	Convenience and adherence
Novel combination product	Potentially high	Very high	New indication or broader market

Patent strength depends on claim breadth, measurable product differences, freedom to operate around excipient prior art, and the ability to link the formulation to clinical or regulatory value.

What commercial opportunities exist for nitazoxanide excipients?

Pediatric global-health products

The largest practical opportunity is a palatable, stable, low-volume pediatric formulation. A product could target:

• Public-health procurement.
• Pediatric hospitals.
• Travel medicine.
• Tropical disease markets.
• Low-resource settings where cold-chain infrastructure is limited.

The formulation should prioritize room-temperature stability, simple reconstitution, clear dosing markings, and a low-cost excipient system.

Sugar-free and alcohol-free liquids

A sugar-free, alcohol-free suspension can differentiate from conventional products. The value is strongest where hospitals, pediatricians, and caregivers prioritize sugar reduction or where excipient restrictions apply.

Dispersible tablets and sachets

Dispersible tablets and dry powders can reduce transport volume and improve storage stability. They may also support use in children who cannot swallow tablets but can take a small volume of dispersed drug.

Unit-dose packaging can reduce dosing errors and improve moisture protection. The tradeoff is higher packaging cost and potentially lower suitability for large-volume public-health programs.

Improved dissolution products

A formulation that reduces dependence on food may have value for travelers, pediatric patients, and patients with inconsistent meal intake. The commercial case requires evidence that the formulation improves pharmacokinetic consistency without increasing adverse effects.

Contract manufacturing and licensing

Licensing opportunities are more likely to involve formulation technology than the active ingredient itself. Relevant assets include:

• Pediatric taste-masking platforms.
• Nanocrystal manufacturing.
• Spray-drying and amorphous dispersion processes.
• Stable dry-suspension platforms.
• Reconstitution and unit-dose packaging systems.

A formulation owner could license technology to regional manufacturers that already have nitazoxanide registration and distribution networks.

How does nitazoxanide compare with competing antiparasitic products?

Product	Main use	Formulation opportunity	Competitive position
Nitazoxanide	Giardia and Cryptosporidium diarrhea	Pediatric suspension, taste masking, dissolution	Genericized, short course
Metronidazole	Giardia and anaerobic infections	Taste masking, liquid stability	Broad generic competition
Tinidazole	Giardia and selected protozoal infections	Single-dose solid dosage forms	Convenience advantage
Paromomycin	Cryptosporidiosis and other infections	Oral liquid and tolerability	Different safety and absorption profile
Albendazole	Helminth infections	Pediatric chewables and suspensions	Broader deworming market

Nitazoxanide’s differentiation is its approved use against Cryptosporidium in immunocompetent patients and its pediatric indication from one year of age. Its weaknesses are generic pricing pressure, food-related absorption considerations, and a smaller market than broad-spectrum antiparasitic products.

What generic launch risks exist for nitazoxanide?

Generic launch risk is moderate for a standard tablet and higher for differentiated pediatric products.

Key risks include:

• Low expected price because of multiple generic suppliers.
• Limited market size for the approved indications.
• Difficulty achieving acceptable pediatric taste.
• Suspension sedimentation and redispersibility failures.
• Preservative or microbial-stability failures.
• Bioequivalence variability caused by low solubility.
• Manufacturing costs for nanocrystal or amorphous systems.
• Regional registration differences.
• Limited commercial value of a formulation patent without payer or prescriber differentiation.

A conventional ANDA may achieve faster approval but face severe price competition. A 505(b)(2) product may obtain stronger differentiation but requires more clinical, pharmacokinetic, and regulatory investment.

What revenue exposure does nitazoxanide create for manufacturers?

Public companies generally do not report nitazoxanide revenue as a separate material segment. Alinia’s commercial contribution is therefore difficult to isolate from public filings, while generic nitazoxanide revenue is typically embedded in broader oral-solid-dose or anti-infective portfolios.

Commercial exposure is concentrated in:

• Pediatric anti-infective sales.
• Hospital and outpatient prescriptions.
• Seasonal or outbreak-related demand.
• Public-health and international tenders.
• Regional distribution agreements.

A manufacturer should assess volume rather than brand-level revenue alone. The short three-day regimen can support high prescription turnover, but the low unit count limits absolute revenue per patient. A differentiated formulation must therefore capture either a premium price, additional geographic registrations, greater institutional access, or a larger treated population.

Key Takeaways

• Nitazoxanide is a genericized small molecule with expired original U.S. exclusivity.
• The principal commercial opportunity is formulation differentiation, not compound protection.
• Pediatric taste masking, sugar-free suspension, improved redispersibility, and unit-dose packaging are the most practical near-term strategies.
• Nanocrystals and amorphous solid dispersions offer stronger technical and patent positions but require greater development investment.
• A food-independent formulation could support a 505(b)(2) strategy if pharmacokinetic benefits are demonstrated.
• Biosimilar competition is irrelevant; generic ANDA competition is the principal market risk.
• Conventional tablets are likely to face price competition, while pediatric and global-health formulations offer better differentiation.
• Patent value will depend on specific formulation claims tied to measurable dissolution, stability, taste, or pharmacokinetic performance.
• Public revenue exposure is difficult to isolate because nitazoxanide sales are generally not reported as a separate line item.

FAQs

Can nitazoxanide be reformulated as an orally disintegrating tablet?

Yes. An orally disintegrating or dispersible tablet could target pediatric and swallowing-impaired patients. The formulation must address taste, rapid disintegration, dose uniformity, moisture sensitivity, and bioequivalence.

Which excipient is best for nitazoxanide taste masking?

No single excipient is universally optimal. Ion-exchange resins, polymer coatings, lipid barriers, and cyclodextrins are credible platforms. Selection depends on dose loading, dissolution requirements, flavor compatibility, and pediatric sensory results.

Is a nitazoxanide fixed-dose combination commercially attractive?

Potentially, but a fixed-dose combination would require a clear clinical or adherence rationale. It would face combination-product compatibility, dose-ratio, clinical-efficacy, and regulatory requirements that exceed those for a standard generic.

Can a sugar-free nitazoxanide suspension receive generic approval?

Yes, if the formulation meets applicable ANDA requirements and demonstrates pharmaceutical equivalence, bioequivalence, stability, microbiological quality, and acceptable excipient safety. A clinically different product may require a 505(b)(2) application.

Are nitazoxanide manufacturing processes patentable?

Yes. Spray-drying, nanocrystal production, solid-dispersion preparation, polymorph control, particle engineering, and specialized suspension processes may support patent claims if they are novel, non-obvious, and tied to reproducible product advantages.

References

1. U.S. Food and Drug Administration. (2023). Alinia (nitazoxanide) tablets and oral suspension: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Food and Drug Administration. (2024). Guidance for industry: 180-day exclusivity and citizen petitions.
4. U.S. Food and Drug Administration. (2023). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA.
5. World Health Organization. (2016). WHO guideline on the pharmacological treatment of diarrhoea. Geneva, Switzerland: World Health Organization.